Evatanepag (0.3-3.0 mg/kg, directly injected into the marrow cavity of the tibia) promotes bone formation in rats[1].
Evatanepag (0.3, 3.0 mg/kg, intranasal administration, from day1 to day4) reduces HDM aeroallergen-induced increased RL response to methacholine in mice[2].
Evatanepag (1 mg/kg, intravenous injection) demonstrates high i.v. clearance (Cl: 56 mL/min/kg) and a short half-life (t1/2: 0.33 h)[1].
| Animal Model: | Rats[1] |
| Dosage: | 0.3, 1.0, 3.0 mg/kg |
| Administration: | Directly injected into the marrow cavity of the tibia
|
| Result: | Dose-dependently increased in bone area, bone mineral content, bone mineral density. |
| Animal Model: | HDM (house dust mite)-sensitized BALB/c mice[2] |
| Dosage: | 0.3 mg/kg, 3 mg/kg |
| Administration: | Intranasal administration, from day1 to day4
|
| Result: | Prevented aeroallergen-driven increased RL (lung resistance) at 0.3 mg/kg.
Prevented the enhanced MC activity by approximately 48% at 3 mg/kg.
|
![2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid Structure](https://www.chemicalbook.com/CAS2/GIF/223488-57-1.gif)
